INTRODUCING OUR NEW LOGO

You may recall voting for our team name – CanREValue (the Canadian Real-world Evidence for Value of Cancer Drugs) at our in-person meeting in May 2018. Since then we have been consulting with various team members about designing a logo for CanREValue and are pleased to show you the results above! Our logo, name, and tagline will be used in our communications and presentations moving forward. Thank you to everyone who participated in the logo development process!

This edition of our newsletter will introduce you to our new Engagement Working Group and our new Research Fellow Victor Nam. As usual, we will also provide updates about current work. Should you have any questions, comments, or feedback, please let us know by emailing WeiFang.Dai@cancercare.on.ca.

Study Objectives:

Objective 1: (ongoing)
- Develop comprehensive understanding of the current state of RWE nationally & internationally

Objective 2: (ongoing)
- Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

Objective 3: (piloting)
- Validate the developed framework through the completion of multi-province RWE project

Objective 4: (ongoing)
- Employ knowledge translation strategies to establish and integrate the final RWE framework

Photo: CanREValue members participate in the 2018 ARCC Conference Plenary Session on Real World Evidence.

From L-R: Dr. Michael Sherar, Dr. Maureen Trudeau, Ms. Carole McMahon, Dr. Michèle de Guise, and Dr. Brian O’Rourke

Not shown but also in the session:
Dr. Jeff Hoch (moderator),
Dr. Kelvin Chan (RWE intro)
**NEW** Engagement Working Group

We are pleased to announce that we have formally established the Engagement Working Group. We are very pleased to announce Dr. Bill Evans as Chair of this group.

**Goal:** To ensure appropriate input from key stakeholders throughout the framework development

**Initial Work**

- Hosted two teleconferences
- Developed strategies to engage clinicians, payers, patients, and industry

Engagement Working Group Members

Chair: Dr. Bill Evans  
(McMaster University)

Tarry Ahuja (CADTH)  
Alexandra Chambers (pCODR)  
Brendalynn Ens (CADTH)  
Scott Gavura (CCO)  
Marjorie Morrison (CAPT)  
Michelle Mujoomdar (CADTH)  
Tamara Rader (CADTH)

Welcome Victor Nam!

Dr. Kelvin Chan is pleased to introduce Mr. Victor (Seungree) Nam, a University of Toronto PhD student who was recently awarded a CIHR Health Services Impact Fellowship (HSIF) to work on the CanREValue project between September 2018 and August 2019. We sat down with Victor to learn a bit more about him:

Q: What is your PhD focused on, and what are your long-term career goals?

I am working with Dr. Julie Gilbert and Dr. Wanrudee Isaranuwatchai, looking at the impact of transitioning of breast cancer survivors from cancer centres to primary care setting. I am very interested in program and health policy evaluations. I am hoping to develop a career as a health economist and improve the efficiency and effectiveness of health care system in Canada.

Q: What aspect of the CanREValue project are you the most excited to work on?

For me, the most exciting aspect of the CanREValue project is the generation of RWE. I am excited to help conducting a drug evaluation for the CanREValue project.

Q: Where will you be working during your fellowship?

Most of my work with Dr. Chan will be at the Cancer Care Ontario office in downtown Toronto. I will be working closely with Wei, Jaclyn, and Rebecca.

Q: How can we reach you?

You can reach me at seungree.nam@cancercare.on.ca – I would love to hear from you and look forward to working with you over the next year!
What’s Happening?

Working Groups

<table>
<thead>
<tr>
<th>Working Group</th>
<th>Updates</th>
</tr>
</thead>
<tbody>
<tr>
<td>RWE Planning and Drug Selection</td>
<td>• Teleconferences in September</td>
</tr>
<tr>
<td></td>
<td>• Refining the criteria for selecting RWE questions and a drug candidate for objective 3</td>
</tr>
<tr>
<td>RWE Data</td>
<td>• Teleconference in September</td>
</tr>
<tr>
<td></td>
<td>• Working on a draft report on the state of data availability and capability for RWE studies across provinces</td>
</tr>
<tr>
<td>RWE Method</td>
<td>• Working on a draft method report</td>
</tr>
<tr>
<td>RWE Uptake and Reassessment</td>
<td>• Members responded to a 3rd survey</td>
</tr>
<tr>
<td></td>
<td>• Teleconference in September</td>
</tr>
<tr>
<td></td>
<td>• Working on a draft report on reassessment</td>
</tr>
<tr>
<td>Stakeholder Engagement</td>
<td>• Formed new working group chaired by Bill Evans</td>
</tr>
<tr>
<td></td>
<td>• Developed strategies to engage clinicians, patients, industries, and payers</td>
</tr>
</tbody>
</table>

Qualitative study:

- Completed additional interviews with industry, patients, international experts, and decision-makers (total n = 26)
- Working on editing and reviewing manuscript on the finding from the study

Recent Presentations

- CADTH/Health Canada/CAPT/IHE RWE Workshop, “Defining “Decision-Grade” Real World Evidence (RWE) and its Role in the Canadian Context: A Design Sprint”, October 21st, 2018
- Presentation and Panel Discussion at CAPT conference, “Are we ready for RWE: What do we need to create RWE from a technical perspective?”, on October 23rd, 2018

Coming Soon….

- Initiate objective 3 to evaluate the framework
- Grant update teleconference – January 9, 2019